Trials / Completed
CompletedNCT03852433
Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)
A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Patients With Chronic Hepatitis Delta
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 175 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy of bulevirtide in combination with pegylated interferon in participants with chronic hepatitis delta (CHD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bulevirtide | Administered via subcutaneous injections |
| DRUG | Peginterferon Alfa-2a (PEG-IFN alfa) | Administered via subcutaneous injections |
Timeline
- Start date
- 2019-05-31
- Primary completion
- 2022-04-05
- Completion
- 2022-09-28
- First posted
- 2019-02-25
- Last updated
- 2024-10-08
- Results posted
- 2024-07-29
Locations
20 sites across 4 countries: France, Moldova, Romania, Russia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03852433. Inclusion in this directory is not an endorsement.